News - Keryx Biopharmaceuticals, Nephrology and Hepatology

Filter

Popular Filters

Keryx Biopharma files for US approval of Zerenex

09-08-2013

Keryx Biopharmaceuticals (Nasdaq: KERX) says it has submitted a New Drug Application to the US Food and…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyNorth AmericaRegulationZerenex

Keryx Biopharma rockets on new Zerenex data and plans to file for approval

29-01-2013

USA-based Keryx Biopharmaceuticals (Nasdaq: KERX) saw its shares close up a whopping 77% to $4.70 in…

BiotechnologyKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenagelRenvelaResearchSanofiZerenex

AEterna Zentaris and Keryx shares tank as cancer drug flops in Ph III

03-04-2012

Canadian drug developer AEterna Zentaris (TSX: AEZ) and US licensee Keryx Pharmaceutical (Nasdaq: KERX)…

AEterna ZentarisKeryx BiopharmaceuticalsLicensingNephrology and HepatologyOncologyperifosinePharmaceuticalResearchZerenex

Back to top